MDT

86.75

-0.41%↓

115.21

+0.1%↑

VEEV

156.87

+3.57%↑

HQY

78.33

+0.27%↑

TLRY

6.47

-1.67%↓

MDT

86.75

-0.41%↓

115.21

+0.1%↑

VEEV

156.87

+3.57%↑

HQY

78.33

+0.27%↑

TLRY

6.47

-1.67%↓

MDT

86.75

-0.41%↓

115.21

+0.1%↑

VEEV

156.87

+3.57%↑

HQY

78.33

+0.27%↑

TLRY

6.47

-1.67%↓

MDT

86.75

-0.41%↓

115.21

+0.1%↑

VEEV

156.87

+3.57%↑

HQY

78.33

+0.27%↑

TLRY

6.47

-1.67%↓

MDT

86.75

-0.41%↓

115.21

+0.1%↑

VEEV

156.87

+3.57%↑

HQY

78.33

+0.27%↑

TLRY

6.47

-1.67%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.37 11.38

Buy Sell

Overview

Share price change

24h

Current

Min

1.23

Max

1.44

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+61.29% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-36M 138M
Previous open	-10.01
Previous close	1.37

News Sentiment

By Acuity

20%

80%

37 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 kwi 2026, 23:44 UTC

Market Talk

Major News Events

Nikkei Likely to Fall After U.S.-Iran Peace Talks Break Down -- Market Talk

12 kwi 2026, 23:38 UTC

Market Talk

Major News Events

Oil Climbs as U.S.-Iran Peace Talks Fail, U.S. Navy Starts Blockade of Strait of Hormuz -- Market Talk

12 kwi 2026, 23:38 UTC

Market Talk

Australia's Upstream Energy Companies Poised for Consensus Earnings Upgrades -- Market Talk

12 kwi 2026, 23:36 UTC

Market Talk

Major News Events

Gold Falls as Dollar Strengthens After U.S.-Iran Peace Talks Collapse -- Market Talk

12 kwi 2026, 23:31 UTC

Market Talk

A2 Milk's Supply Issues Likely Temporary -- Market Talk

12 kwi 2026, 23:09 UTC

Market Talk

Major News Events

Australian Dollar Hammered by Blockade of Iran Ports -- Market Talk

12 kwi 2026, 23:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 kwi 2026, 23:06 UTC

Market Talk

Australian Dollar Ripe for a Downward Correction -- Market Talk

12 kwi 2026, 22:56 UTC

Major News Events

Spot Gold Falls 1.9% to $4,658.65 per Ounce

12 kwi 2026, 22:54 UTC

Major News Events

Front-Month Brent Crude Oil Futures Rise 7.6% to $102.42 per Barrel

12 kwi 2026, 22:53 UTC

Major News Events

Front-Month WTI Crude Oil Futures Rise 8.3% to $104.56 per Barrel, ICE Data Show

12 kwi 2026, 22:51 UTC

Major News Events

Front-Month Crude Oil Futures Climb After U.S.-Iran Peace Talks Break Down

12 kwi 2026, 22:50 UTC

Market Talk

Major News Events

US Dollar Climbs Amid Broad Risk Off Mood In FX Market -- Market Talk

12 kwi 2026, 22:37 UTC

Market Talk

Major News Events

Australian Dollar Under Fire as Middle East Tensions Ratchet Up Again -- Market Talk

11 kwi 2026, 08:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

11 kwi 2026, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

11 kwi 2026, 08:20 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

11 kwi 2026, 00:00 UTC

Earnings

Acquisitions, Mergers, Takeovers

Big Yachts, Big Bucks -- Barrons.com

10 kwi 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 kwi 2026, 21:01 UTC

Earnings

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

10 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 kwi 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 kwi 2026, 20:10 UTC

Acquisitions, Mergers, Takeovers

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 kwi 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10 kwi 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 kwi 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 kwi 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 kwi 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

61.29% upside

12 Months Forecast

Average 2 USD 61.29%

High 2 USD

Low 2 USD

Based on 3 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

37 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.